FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Market Intelligence Analysis

AI-Powered
Why This Matters

The FDA chief has expressed concerns that the US is falling behind China in early drug development, citing three key bottlenecks in the approval process.

Market Impact

Market impact analysis based on bearish sentiment with 80% confidence.

Sentiment
Bearish
AI Confidence
80%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Makary pointed to three bottlenecks: hospital contracting, ethical reviews and approvals and the Investigational New Drug applications process

Continue Reading
Full article on CNBC
Read Full Article
Original article published by CNBC on February 18, 2026.
Analysis and insights provided by AnalystMarkets AI.